DCM
CLYM

Driehaus Capital Management’s Climb Bio CLYM Stock Holding History

Driehaus Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.12M Hold
600,946
– – 0.03% 292
2025
Q4 		$2.4M Buy
+600,946
New +$1.44M 0.02% 329
2024
Q4 		– Sell
-612,387
Closed -$3.12M – 463
2024
Q3 		$3.12M Sell
612,387
-83,670
-12% -$592K 0.03% 292
2024
Q2 		$4.95M Sell
696,057
-115,623
-14% -$770K 0.05% 259
2024
Q1 		$2.22M Hold
811,680
– – 0.02% 304
2023
Q4 		$2.19M Hold
811,680
– – 0.03% 294
2023
Q3 		$2.13M Buy
811,680
+1,087
+0.1% +$2.96K 0.03% 303
2023
Q2 		$2.27M Buy
810,593
+136,909
+20% +$416K 0.03% 296
2023
Q1 		$1.95M Buy
673,684
+121,742
+22% +$418K 0.03% 318
2022
Q4 		$2.03M Buy
551,942
+203,371
+58% +$603K 0.03% 293
2022
Q3 		$1.13M Buy
+348,571
New +$1.11M 0.02% 304

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Driehaus Capital Management's CLYM Position: Q1 2026 in Review

Driehaus Capital Management held its Climb Bio (CLYM) position steady in Q1 2026 at 600,946 shares worth $4.12M. The position accounts for 0.03% of the portfolio, ranked #292.

Driehaus Capital Management first reported a position in CLYM in Q3 2022 and has held it in 11 quarters since. The position peaked at $4.95M in Q2 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Driehaus Capital Management held 600,946 shares of Climb Bio worth $4.12M as of Q1 2026.
  • Driehaus Capital Management left its Climb Bio share count unchanged in Q1 2026.
  • Climb Bio made up 0.03% of Driehaus Capital Management's portfolio in Q1 2026, its #292 holding.
  • Driehaus Capital Management first reported a position in Climb Bio in Q3 2022 and has held it in 11 quarters since.
  • Driehaus Capital Management's Climb Bio position peaked at $4.95M in Q2 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.